Sustained successful peanut oral immunotherapy associated with low basophil activation and peanut-specific IgE
Oral immunotherapy (OIT) can successfully desensitize many peanut-allergic subjects, but clinical tolerance diminishes over time on discontinuation, or low-dose maintenance, of peanut. Therefore, to improve the efficacy and sustainability of such therapy, we sought to identify biomarkers and clinica...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Tsai, Mindy [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2020 |
|---|
| Schlagwörter: |
|---|
| Umfang: |
8082 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Antidiabetic treatment in elderly patients with low performance status admitted to internal medicine ward - Papakitsou, I. ELSEVIER, 2022, official publication of the American Academy of Allergy, Asthma and Immunology, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:145 ; year:2020 ; number:3 ; pages:885-8966 ; extent:8082 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.jaci.2019.10.038 |
|---|
| Katalog-ID: |
ELV049595385 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV049595385 | ||
| 003 | DE-627 | ||
| 005 | 20230624154558.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200518s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jaci.2019.10.038 |2 doi | |
| 028 | 5 | 2 | |a /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000000933.pica |
| 035 | |a (DE-627)ELV049595385 | ||
| 035 | |a (ELSEVIER)S0091-6749(19)31620-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 44.85 |2 bkl | ||
| 100 | 1 | |a Tsai, Mindy |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Sustained successful peanut oral immunotherapy associated with low basophil activation and peanut-specific IgE |
| 264 | 1 | |c 2020 | |
| 300 | |a 8082 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Oral immunotherapy (OIT) can successfully desensitize many peanut-allergic subjects, but clinical tolerance diminishes over time on discontinuation, or low-dose maintenance, of peanut. Therefore, to improve the efficacy and sustainability of such therapy, we sought to identify biomarkers and clinical tools that can predict therapeutic outcomes and monitor treatment responses. | ||
| 650 | 7 | |a peanut-specific IgE |2 Elsevier | |
| 650 | 7 | |a CD63 |2 Elsevier | |
| 650 | 7 | |a peanut allergy |2 Elsevier | |
| 650 | 7 | |a peanut-specific IgG4 |2 Elsevier | |
| 650 | 7 | |a CD203c |2 Elsevier | |
| 650 | 7 | |a biomarkers |2 Elsevier | |
| 650 | 7 | |a basophil activation test |2 Elsevier | |
| 650 | 7 | |a oral immunotherapy |2 Elsevier | |
| 650 | 7 | |a Basophil |2 Elsevier | |
| 700 | 1 | |a Mukai, Kaori |4 oth | |
| 700 | 1 | |a Chinthrajah, R. Sharon |4 oth | |
| 700 | 1 | |a Nadeau, Kari C. |4 oth | |
| 700 | 1 | |a Galli, Stephen J. |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier |a Papakitsou, I. ELSEVIER |t Antidiabetic treatment in elderly patients with low performance status admitted to internal medicine ward |d 2022 |d official publication of the American Academy of Allergy, Asthma and Immunology |g Amsterdam [u.a.] |w (DE-627)ELV000021164 |
| 773 | 1 | 8 | |g volume:145 |g year:2020 |g number:3 |g pages:885-8966 |g extent:8082 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.jaci.2019.10.038 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 44.85 |j Kardiologie |j Angiologie |q VZ |
| 951 | |a AR | ||
| 952 | |d 145 |j 2020 |e 3 |h 885-8966 |g 8082 | ||
| author_variant |
m t mt |
|---|---|
| matchkey_str |
tsaimindymukaikaorichinthrajahrsharonnad:2020----:utiescesupauoaimnteaysoitdihobspiatv |
| hierarchy_sort_str |
2020 |
| bklnumber |
44.85 |
| publishDate |
2020 |
| allfields |
10.1016/j.jaci.2019.10.038 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000000933.pica (DE-627)ELV049595385 (ELSEVIER)S0091-6749(19)31620-3 DE-627 ger DE-627 rakwb eng 610 VZ 44.85 bkl Tsai, Mindy verfasserin aut Sustained successful peanut oral immunotherapy associated with low basophil activation and peanut-specific IgE 2020 8082 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Oral immunotherapy (OIT) can successfully desensitize many peanut-allergic subjects, but clinical tolerance diminishes over time on discontinuation, or low-dose maintenance, of peanut. Therefore, to improve the efficacy and sustainability of such therapy, we sought to identify biomarkers and clinical tools that can predict therapeutic outcomes and monitor treatment responses. peanut-specific IgE Elsevier CD63 Elsevier peanut allergy Elsevier peanut-specific IgG4 Elsevier CD203c Elsevier biomarkers Elsevier basophil activation test Elsevier oral immunotherapy Elsevier Basophil Elsevier Mukai, Kaori oth Chinthrajah, R. Sharon oth Nadeau, Kari C. oth Galli, Stephen J. oth Enthalten in Elsevier Papakitsou, I. ELSEVIER Antidiabetic treatment in elderly patients with low performance status admitted to internal medicine ward 2022 official publication of the American Academy of Allergy, Asthma and Immunology Amsterdam [u.a.] (DE-627)ELV000021164 volume:145 year:2020 number:3 pages:885-8966 extent:8082 https://doi.org/10.1016/j.jaci.2019.10.038 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.85 Kardiologie Angiologie VZ AR 145 2020 3 885-8966 8082 |
| spelling |
10.1016/j.jaci.2019.10.038 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000000933.pica (DE-627)ELV049595385 (ELSEVIER)S0091-6749(19)31620-3 DE-627 ger DE-627 rakwb eng 610 VZ 44.85 bkl Tsai, Mindy verfasserin aut Sustained successful peanut oral immunotherapy associated with low basophil activation and peanut-specific IgE 2020 8082 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Oral immunotherapy (OIT) can successfully desensitize many peanut-allergic subjects, but clinical tolerance diminishes over time on discontinuation, or low-dose maintenance, of peanut. Therefore, to improve the efficacy and sustainability of such therapy, we sought to identify biomarkers and clinical tools that can predict therapeutic outcomes and monitor treatment responses. peanut-specific IgE Elsevier CD63 Elsevier peanut allergy Elsevier peanut-specific IgG4 Elsevier CD203c Elsevier biomarkers Elsevier basophil activation test Elsevier oral immunotherapy Elsevier Basophil Elsevier Mukai, Kaori oth Chinthrajah, R. Sharon oth Nadeau, Kari C. oth Galli, Stephen J. oth Enthalten in Elsevier Papakitsou, I. ELSEVIER Antidiabetic treatment in elderly patients with low performance status admitted to internal medicine ward 2022 official publication of the American Academy of Allergy, Asthma and Immunology Amsterdam [u.a.] (DE-627)ELV000021164 volume:145 year:2020 number:3 pages:885-8966 extent:8082 https://doi.org/10.1016/j.jaci.2019.10.038 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.85 Kardiologie Angiologie VZ AR 145 2020 3 885-8966 8082 |
| allfields_unstemmed |
10.1016/j.jaci.2019.10.038 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000000933.pica (DE-627)ELV049595385 (ELSEVIER)S0091-6749(19)31620-3 DE-627 ger DE-627 rakwb eng 610 VZ 44.85 bkl Tsai, Mindy verfasserin aut Sustained successful peanut oral immunotherapy associated with low basophil activation and peanut-specific IgE 2020 8082 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Oral immunotherapy (OIT) can successfully desensitize many peanut-allergic subjects, but clinical tolerance diminishes over time on discontinuation, or low-dose maintenance, of peanut. Therefore, to improve the efficacy and sustainability of such therapy, we sought to identify biomarkers and clinical tools that can predict therapeutic outcomes and monitor treatment responses. peanut-specific IgE Elsevier CD63 Elsevier peanut allergy Elsevier peanut-specific IgG4 Elsevier CD203c Elsevier biomarkers Elsevier basophil activation test Elsevier oral immunotherapy Elsevier Basophil Elsevier Mukai, Kaori oth Chinthrajah, R. Sharon oth Nadeau, Kari C. oth Galli, Stephen J. oth Enthalten in Elsevier Papakitsou, I. ELSEVIER Antidiabetic treatment in elderly patients with low performance status admitted to internal medicine ward 2022 official publication of the American Academy of Allergy, Asthma and Immunology Amsterdam [u.a.] (DE-627)ELV000021164 volume:145 year:2020 number:3 pages:885-8966 extent:8082 https://doi.org/10.1016/j.jaci.2019.10.038 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.85 Kardiologie Angiologie VZ AR 145 2020 3 885-8966 8082 |
| allfieldsGer |
10.1016/j.jaci.2019.10.038 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000000933.pica (DE-627)ELV049595385 (ELSEVIER)S0091-6749(19)31620-3 DE-627 ger DE-627 rakwb eng 610 VZ 44.85 bkl Tsai, Mindy verfasserin aut Sustained successful peanut oral immunotherapy associated with low basophil activation and peanut-specific IgE 2020 8082 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Oral immunotherapy (OIT) can successfully desensitize many peanut-allergic subjects, but clinical tolerance diminishes over time on discontinuation, or low-dose maintenance, of peanut. Therefore, to improve the efficacy and sustainability of such therapy, we sought to identify biomarkers and clinical tools that can predict therapeutic outcomes and monitor treatment responses. peanut-specific IgE Elsevier CD63 Elsevier peanut allergy Elsevier peanut-specific IgG4 Elsevier CD203c Elsevier biomarkers Elsevier basophil activation test Elsevier oral immunotherapy Elsevier Basophil Elsevier Mukai, Kaori oth Chinthrajah, R. Sharon oth Nadeau, Kari C. oth Galli, Stephen J. oth Enthalten in Elsevier Papakitsou, I. ELSEVIER Antidiabetic treatment in elderly patients with low performance status admitted to internal medicine ward 2022 official publication of the American Academy of Allergy, Asthma and Immunology Amsterdam [u.a.] (DE-627)ELV000021164 volume:145 year:2020 number:3 pages:885-8966 extent:8082 https://doi.org/10.1016/j.jaci.2019.10.038 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.85 Kardiologie Angiologie VZ AR 145 2020 3 885-8966 8082 |
| allfieldsSound |
10.1016/j.jaci.2019.10.038 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000000933.pica (DE-627)ELV049595385 (ELSEVIER)S0091-6749(19)31620-3 DE-627 ger DE-627 rakwb eng 610 VZ 44.85 bkl Tsai, Mindy verfasserin aut Sustained successful peanut oral immunotherapy associated with low basophil activation and peanut-specific IgE 2020 8082 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Oral immunotherapy (OIT) can successfully desensitize many peanut-allergic subjects, but clinical tolerance diminishes over time on discontinuation, or low-dose maintenance, of peanut. Therefore, to improve the efficacy and sustainability of such therapy, we sought to identify biomarkers and clinical tools that can predict therapeutic outcomes and monitor treatment responses. peanut-specific IgE Elsevier CD63 Elsevier peanut allergy Elsevier peanut-specific IgG4 Elsevier CD203c Elsevier biomarkers Elsevier basophil activation test Elsevier oral immunotherapy Elsevier Basophil Elsevier Mukai, Kaori oth Chinthrajah, R. Sharon oth Nadeau, Kari C. oth Galli, Stephen J. oth Enthalten in Elsevier Papakitsou, I. ELSEVIER Antidiabetic treatment in elderly patients with low performance status admitted to internal medicine ward 2022 official publication of the American Academy of Allergy, Asthma and Immunology Amsterdam [u.a.] (DE-627)ELV000021164 volume:145 year:2020 number:3 pages:885-8966 extent:8082 https://doi.org/10.1016/j.jaci.2019.10.038 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.85 Kardiologie Angiologie VZ AR 145 2020 3 885-8966 8082 |
| language |
English |
| source |
Enthalten in Antidiabetic treatment in elderly patients with low performance status admitted to internal medicine ward Amsterdam [u.a.] volume:145 year:2020 number:3 pages:885-8966 extent:8082 |
| sourceStr |
Enthalten in Antidiabetic treatment in elderly patients with low performance status admitted to internal medicine ward Amsterdam [u.a.] volume:145 year:2020 number:3 pages:885-8966 extent:8082 |
| format_phy_str_mv |
Article |
| bklname |
Kardiologie Angiologie |
| institution |
findex.gbv.de |
| topic_facet |
peanut-specific IgE CD63 peanut allergy peanut-specific IgG4 CD203c biomarkers basophil activation test oral immunotherapy Basophil |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
Antidiabetic treatment in elderly patients with low performance status admitted to internal medicine ward |
| authorswithroles_txt_mv |
Tsai, Mindy @@aut@@ Mukai, Kaori @@oth@@ Chinthrajah, R. Sharon @@oth@@ Nadeau, Kari C. @@oth@@ Galli, Stephen J. @@oth@@ |
| publishDateDaySort_date |
2020-01-01T00:00:00Z |
| hierarchy_top_id |
ELV000021164 |
| dewey-sort |
3610 |
| id |
ELV049595385 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV049595385</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230624154558.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">200518s2020 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.jaci.2019.10.038</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000000933.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV049595385</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0091-6749(19)31620-3</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.85</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Tsai, Mindy</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Sustained successful peanut oral immunotherapy associated with low basophil activation and peanut-specific IgE</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">8082</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Oral immunotherapy (OIT) can successfully desensitize many peanut-allergic subjects, but clinical tolerance diminishes over time on discontinuation, or low-dose maintenance, of peanut. Therefore, to improve the efficacy and sustainability of such therapy, we sought to identify biomarkers and clinical tools that can predict therapeutic outcomes and monitor treatment responses.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">peanut-specific IgE</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">CD63</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">peanut allergy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">peanut-specific IgG4</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">CD203c</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">biomarkers</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">basophil activation test</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">oral immunotherapy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Basophil</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mukai, Kaori</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Chinthrajah, R. Sharon</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nadeau, Kari C.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Galli, Stephen J.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">Papakitsou, I. ELSEVIER</subfield><subfield code="t">Antidiabetic treatment in elderly patients with low performance status admitted to internal medicine ward</subfield><subfield code="d">2022</subfield><subfield code="d">official publication of the American Academy of Allergy, Asthma and Immunology</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV000021164</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:145</subfield><subfield code="g">year:2020</subfield><subfield code="g">number:3</subfield><subfield code="g">pages:885-8966</subfield><subfield code="g">extent:8082</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.jaci.2019.10.038</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.85</subfield><subfield code="j">Kardiologie</subfield><subfield code="j">Angiologie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">145</subfield><subfield code="j">2020</subfield><subfield code="e">3</subfield><subfield code="h">885-8966</subfield><subfield code="g">8082</subfield></datafield></record></collection>
|
| author |
Tsai, Mindy |
| spellingShingle |
Tsai, Mindy ddc 610 bkl 44.85 Elsevier peanut-specific IgE Elsevier CD63 Elsevier peanut allergy Elsevier peanut-specific IgG4 Elsevier CD203c Elsevier biomarkers Elsevier basophil activation test Elsevier oral immunotherapy Elsevier Basophil Sustained successful peanut oral immunotherapy associated with low basophil activation and peanut-specific IgE |
| authorStr |
Tsai, Mindy |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV000021164 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 VZ 44.85 bkl Sustained successful peanut oral immunotherapy associated with low basophil activation and peanut-specific IgE peanut-specific IgE Elsevier CD63 Elsevier peanut allergy Elsevier peanut-specific IgG4 Elsevier CD203c Elsevier biomarkers Elsevier basophil activation test Elsevier oral immunotherapy Elsevier Basophil Elsevier |
| topic |
ddc 610 bkl 44.85 Elsevier peanut-specific IgE Elsevier CD63 Elsevier peanut allergy Elsevier peanut-specific IgG4 Elsevier CD203c Elsevier biomarkers Elsevier basophil activation test Elsevier oral immunotherapy Elsevier Basophil |
| topic_unstemmed |
ddc 610 bkl 44.85 Elsevier peanut-specific IgE Elsevier CD63 Elsevier peanut allergy Elsevier peanut-specific IgG4 Elsevier CD203c Elsevier biomarkers Elsevier basophil activation test Elsevier oral immunotherapy Elsevier Basophil |
| topic_browse |
ddc 610 bkl 44.85 Elsevier peanut-specific IgE Elsevier CD63 Elsevier peanut allergy Elsevier peanut-specific IgG4 Elsevier CD203c Elsevier biomarkers Elsevier basophil activation test Elsevier oral immunotherapy Elsevier Basophil |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
k m km r s c rs rsc k c n kc kcn s j g sj sjg |
| hierarchy_parent_title |
Antidiabetic treatment in elderly patients with low performance status admitted to internal medicine ward |
| hierarchy_parent_id |
ELV000021164 |
| dewey-tens |
610 - Medicine & health |
| hierarchy_top_title |
Antidiabetic treatment in elderly patients with low performance status admitted to internal medicine ward |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV000021164 |
| title |
Sustained successful peanut oral immunotherapy associated with low basophil activation and peanut-specific IgE |
| ctrlnum |
(DE-627)ELV049595385 (ELSEVIER)S0091-6749(19)31620-3 |
| title_full |
Sustained successful peanut oral immunotherapy associated with low basophil activation and peanut-specific IgE |
| author_sort |
Tsai, Mindy |
| journal |
Antidiabetic treatment in elderly patients with low performance status admitted to internal medicine ward |
| journalStr |
Antidiabetic treatment in elderly patients with low performance status admitted to internal medicine ward |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
2020 |
| contenttype_str_mv |
zzz |
| container_start_page |
885 |
| author_browse |
Tsai, Mindy |
| container_volume |
145 |
| physical |
8082 |
| class |
610 VZ 44.85 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Tsai, Mindy |
| doi_str_mv |
10.1016/j.jaci.2019.10.038 |
| dewey-full |
610 |
| title_sort |
sustained successful peanut oral immunotherapy associated with low basophil activation and peanut-specific ige |
| title_auth |
Sustained successful peanut oral immunotherapy associated with low basophil activation and peanut-specific IgE |
| abstract |
Oral immunotherapy (OIT) can successfully desensitize many peanut-allergic subjects, but clinical tolerance diminishes over time on discontinuation, or low-dose maintenance, of peanut. Therefore, to improve the efficacy and sustainability of such therapy, we sought to identify biomarkers and clinical tools that can predict therapeutic outcomes and monitor treatment responses. |
| abstractGer |
Oral immunotherapy (OIT) can successfully desensitize many peanut-allergic subjects, but clinical tolerance diminishes over time on discontinuation, or low-dose maintenance, of peanut. Therefore, to improve the efficacy and sustainability of such therapy, we sought to identify biomarkers and clinical tools that can predict therapeutic outcomes and monitor treatment responses. |
| abstract_unstemmed |
Oral immunotherapy (OIT) can successfully desensitize many peanut-allergic subjects, but clinical tolerance diminishes over time on discontinuation, or low-dose maintenance, of peanut. Therefore, to improve the efficacy and sustainability of such therapy, we sought to identify biomarkers and clinical tools that can predict therapeutic outcomes and monitor treatment responses. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA |
| container_issue |
3 |
| title_short |
Sustained successful peanut oral immunotherapy associated with low basophil activation and peanut-specific IgE |
| url |
https://doi.org/10.1016/j.jaci.2019.10.038 |
| remote_bool |
true |
| author2 |
Mukai, Kaori Chinthrajah, R. Sharon Nadeau, Kari C. Galli, Stephen J. |
| author2Str |
Mukai, Kaori Chinthrajah, R. Sharon Nadeau, Kari C. Galli, Stephen J. |
| ppnlink |
ELV000021164 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth |
| doi_str |
10.1016/j.jaci.2019.10.038 |
| up_date |
2024-07-06T22:01:16.924Z |
| _version_ |
1803868728904908800 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV049595385</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230624154558.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">200518s2020 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.jaci.2019.10.038</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000000933.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV049595385</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0091-6749(19)31620-3</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.85</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Tsai, Mindy</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Sustained successful peanut oral immunotherapy associated with low basophil activation and peanut-specific IgE</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">8082</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Oral immunotherapy (OIT) can successfully desensitize many peanut-allergic subjects, but clinical tolerance diminishes over time on discontinuation, or low-dose maintenance, of peanut. Therefore, to improve the efficacy and sustainability of such therapy, we sought to identify biomarkers and clinical tools that can predict therapeutic outcomes and monitor treatment responses.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">peanut-specific IgE</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">CD63</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">peanut allergy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">peanut-specific IgG4</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">CD203c</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">biomarkers</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">basophil activation test</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">oral immunotherapy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Basophil</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mukai, Kaori</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Chinthrajah, R. Sharon</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nadeau, Kari C.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Galli, Stephen J.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">Papakitsou, I. ELSEVIER</subfield><subfield code="t">Antidiabetic treatment in elderly patients with low performance status admitted to internal medicine ward</subfield><subfield code="d">2022</subfield><subfield code="d">official publication of the American Academy of Allergy, Asthma and Immunology</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV000021164</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:145</subfield><subfield code="g">year:2020</subfield><subfield code="g">number:3</subfield><subfield code="g">pages:885-8966</subfield><subfield code="g">extent:8082</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.jaci.2019.10.038</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.85</subfield><subfield code="j">Kardiologie</subfield><subfield code="j">Angiologie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">145</subfield><subfield code="j">2020</subfield><subfield code="e">3</subfield><subfield code="h">885-8966</subfield><subfield code="g">8082</subfield></datafield></record></collection>
|
| score |
7.3986235 |